Amgen, Inc. and Bioeq/Formycon have each moved their biosimilar Stelara (ustekinumab) candidates into Phase III clinical studies, representing a significant step in the race to develop one of the most lucrative ‘next wave’ biosimilar opportunities.
Amgen And Bioeq Shuttle Stelara Biosimilars Into Phase III Trials
Amgen Study Involves FDA-Approved Product
Almost in tandem, Amgen and Bioeq, with partner Formycon, have advanced their biosimilar Stelara (ustekinumab) candidates into Phase III clinical trials. Both sponsors are aiming to wrap their studies up in 2022.
